Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2023-03-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于BPI-472372片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration (NMPA) for a new drug candidate. It includes details about the drug, regulatory approval, and risk warnings. The document is short (1122 characters) and does not contain financial data, earnings, or management discussion. It is an official announcement of a regulatory approval event, not a financial report or detailed management report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-03-13 Chinese
关于BPB-101双抗注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about receiving clinical trial approval from a regulatory authority (NMPA) for a new drug candidate. It includes details about the drug, the approval notice, and a risk disclaimer. The document length is short (1327 characters) and it is an announcement of an event rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-10 Chinese
关于股东股份质押变动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding changes in shareholder stock pledges by a controlling shareholder and related parties. It details the number of shares pledged, percentages of total shares, and risk assessments related to these pledges. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledge changes, which fits the category of Regulatory Filings (RNS) as it does not fall under more specific categories like Major Shareholding Notification (MRQ) or Director's Dealing (DIRS), since it concerns pledge changes rather than share ownership changes or insider trades. The document length is short (1915 characters), and it is a standalone announcement of share pledge changes.
2023-03-01 Chinese
关于股东股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the release of pledged shares by a shareholder. It details the number of shares released from pledge, the shareholder involved, and the status of pledged shares. There is no financial statement, earnings data, or management discussion. The document is short (2218 characters) and focuses on share pledge status, which is a capital structure related update. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2023-02-08 Chinese
关于投资杭州贝橙创业投资合伙企业（有限合伙）的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of an investment by the company 贝达药业股份有限公司 into a limited partnership fund (杭州贝橙创业投资合伙企业). It details the investment amount, the partners involved, their contributions, and the strategic rationale and risks associated with the investment. There are no financial statements, quarterly or annual results, or audit information presented. The document is a corporate announcement about a capital investment transaction and its progress, not a financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2848 characters, which is consistent with an announcement rather than a full report.
2023-02-02 Chinese
关于股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a shareholder (Ningbo Kaiming Investment Management Partnership) of Betta Pharmaceuticals Co., Ltd. It details the number of shares released from pledge, the proportion of shares pledged before and after, and the impact on the company's shareholding structure. There is no financial data, no discussion of financial results, no management commentary, no legal proceedings, no merger or acquisition activity, and no mention of an annual or interim report. The document is a regulatory announcement about share pledge status and changes, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Major Shareholding Notification or Director's Dealing. The document length is short (2024 characters), and it is a standalone announcement, not a report or presentation. Therefore, the best classification is Regulatory Filings (RNS).
2023-02-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.